Solstein Capital’s NeoGenomics NEO Stock Holding History

Solstein Capital’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,380	Closed	-$153K	–	495
2021 Q2	$153K	Sell	3,380 -410	-11%	-$18.2K	0.19%	124
2021 Q1	$183K	Buy	+3,790	New	+$197K	0.25%	108

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Solstein Capital's NEO Position: Q3 2021 in Review

Solstein Capital sold out of NeoGenomics (NEO) in Q3 2021, closing a stake of 3,380 shares — an estimated $153K sold.

Solstein Capital first reported a position in NEO in Q1 2021 and held it in 2 quarters. The position peaked at $183K in Q1 2021. 324 funds tracked by Wall St. Rank hold NEO as of Q3 2021.

Solstein Capital reported no remaining NeoGenomics position as of Q3 2021 after selling out during the quarter.
Solstein Capital sold 3,380 NeoGenomics shares in Q3 2021, an estimated $153K.
Solstein Capital first reported a position in NeoGenomics in Q1 2021 and held it in 2 quarters.
Solstein Capital's NeoGenomics position peaked at $183K in Q1 2021.
324 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2021.

Based on Solstein Capital's 13F filing for Q3 2021, filed 27 Oct 2021.